Migraine might have a new potent preventive treatment on the market in the near future. The new breakthrough approach towards migraine treatment aims at targeting and inhibiting calcitonin gene–related peptide (CGPR).
Four drug developing firms have ongoing clinical trials with drugs targeting CGPR. These are Amgen/Novartis product erenumab (AMG334); Alder Pharmaceuticals’’ product ALD403 and Teva Pharmaceuticals’ product TEV-48125. Each of the monoclonal antibodies has a different mechanism of action. However, they were all described as sharing several key characteristics, including high specificity in their mechanisms of action; long . . .